Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 102Thyroid Neoplasms 40Thyroid Cancer, Papillary 36Carcinoid Tumor 32Neoplasms 28Multiple Endocrine Neoplasia Type 1 22Adenocarcinoma, Follicular 22Thyroid Carcinoma, Anaplastic 21Neoplasm Metastasis 21Pituitary Neoplasms 20Carcinoma, Neuroendocrine 20Pheochromocytoma 19Carcinoma, Medullary 19Paraganglioma 17Carcinoma, Non-Small-Cell Lung 17Somatostatinoma 16Adrenocortical Carcinoma 16Pancreatic Neoplasms 14Carcinoma, Islet Cell 14Insulinoma 12Glucagonoma 12Adenoma, Islet Cell 12Gastrinoma 11Colorectal Neoplasms 11Breast Neoplasms 11Sarcoma 10Melanoma 10Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Renal Cell 10Pituitary ACTH Hypersecretion 9

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Differentiated Thyroid Cancer (DTC) × Endocrine × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡